tetano
Editor, Senior Moderator
Infect Drug Resist
. 2022 Feb 3;15:373-385.
doi: 10.2147/IDR.S344099. eCollection 2022.
SARS-CoV-2 E484K Mutation Narrative Review: Epidemiology, Immune Escape, Clinical Implications, and Future Considerations
Wan-Ting Yang[SUP] #[/SUP][SUP] 1 [/SUP], Wei-Hsuan Huang[SUP] #[/SUP][SUP] 1 [/SUP], Tsai-Ling Liao[SUP] 2 [/SUP], Tzu-Hung Hsiao[SUP] 2 [/SUP], Han-Ni Chuang[SUP] 2 [/SUP], Po-Yu Liu[SUP] 1 3 4 [/SUP]
Affiliations
Abstract
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spread rapidly over the world and claimed million lives. The virus evolves constantly, and a swarm of mutants is a now major concern globally. Distinct variants could have independently converged on same mutation, despite being detected in different geographic regions, which suggested it could confer an evolutionary advantage. E484K has rapidly emerged and has frequently been detected in several SARS-CoV-2 variants of concern. In this study, we review the epidemiology and impact of E484K, its effects on neutralizing effect of several monoclonal antibodies, convalescent plasma, and post-vaccine sera.
Keywords: E484K; SARS-CoV-2 convalescent sera treatment; SARS-CoV-2 variant; coronavirus spike glycoprotein; monoclonal antibody; vaccine.
. 2022 Feb 3;15:373-385.
doi: 10.2147/IDR.S344099. eCollection 2022.
SARS-CoV-2 E484K Mutation Narrative Review: Epidemiology, Immune Escape, Clinical Implications, and Future Considerations
Wan-Ting Yang[SUP] #[/SUP][SUP] 1 [/SUP], Wei-Hsuan Huang[SUP] #[/SUP][SUP] 1 [/SUP], Tsai-Ling Liao[SUP] 2 [/SUP], Tzu-Hung Hsiao[SUP] 2 [/SUP], Han-Ni Chuang[SUP] 2 [/SUP], Po-Yu Liu[SUP] 1 3 4 [/SUP]
Affiliations
- PMID: 35140483
- PMCID: PMC8820839
- DOI: 10.2147/IDR.S344099
Abstract
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spread rapidly over the world and claimed million lives. The virus evolves constantly, and a swarm of mutants is a now major concern globally. Distinct variants could have independently converged on same mutation, despite being detected in different geographic regions, which suggested it could confer an evolutionary advantage. E484K has rapidly emerged and has frequently been detected in several SARS-CoV-2 variants of concern. In this study, we review the epidemiology and impact of E484K, its effects on neutralizing effect of several monoclonal antibodies, convalescent plasma, and post-vaccine sera.
Keywords: E484K; SARS-CoV-2 convalescent sera treatment; SARS-CoV-2 variant; coronavirus spike glycoprotein; monoclonal antibody; vaccine.